Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure

Hypertension

Volumn 33, Issue 6, 1999, Pages 1374-1378

  Yasuda, Satoshi ^a   Goto, Yoichi ^a   Sumida, Hitoshi ^a   Noguchi, Teruo ^a   Baba, Takeshi ^a   Miyazaki, Shunichi ^a   Nonogi, Hiroshi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Angiotensin; Endothelium; Growth factors; Heart failure; Natriuretic peptides

Indexed keywords

ANGIOTENSIN; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HEPARIN; IMIDAPRIL; NITRATE; SCATTER FACTOR; TEMOCAPRIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; NATRIURESIS; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0033051875     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.33.6.1374     Document Type: Article

References (36)

1. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of hepatocyte growth factor. Nature (Lond.). 1989;342:440-443.
2. Matsumoto K, Nakamura T. Emerging multipotent aspects hepatocyte growth factor. J Biochem. 1996;119:591-600.
3. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, Yamada K, Hayashi S, Yo Y, Matsumoto K, Nakamura T, Ogihara T. Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun. 1995;215:483-488.
4. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, Yamada K, Hayashi S, Yo Y, Matsumoto K, Nakamura T, Ogihara T. Differential regulation of local hepatocyte growth factor, endothelium-specific growth factor, production in vascular cells. J Hypertens. 1996;14:S70. Abstract.
5. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, Yamada K, Hayashi S, Yo Y, Nakano H, Matsumoto K, Nakamura T, Ogihara T. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens. 1996;14:1067-1072.
6. Nakamura Y, Morishita R, Nakamura S, Aoki M, Moriguchi A, Matsumoto K, Nakamura T, Higaki J, Ogihara T. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension. 1996;28:409-413.
7. Nakano N, Moriguchi A, Morishia R, Kida I, Tomita N, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats. Hypertension. 1997;30:1448-1454.
8. Nakamura S, Moriguchi A, Morishita R, Aoki M, Yo Y, Hayashi S, Nakano N, Katsuya T, Nakata S, Takami S, Matsumoto K, Nakamura T, Higaki J, Ogihara T. A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension. Biochem Biophys Res Commun. 1998;242:238-243.
9. Matsumori A, Furukawa Y, Hashimoto T, Ono K, Shioi T, Okada M, Iwasaki A, Nishio R, Sasayama S. Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction. Biochem Biophys Res Commun. 1996;221:391-395.
10. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation. 1997;95:2552-2558.
11. Yang R, Bunting S, Ko A, Schwall R, Jin H. Hemodynamic effects of scatter factor in conscious rats. J Cardiovasc Pharmacol. 1997;30:294-301.
12. Ueda H, Sawa Y, Kawahira Y, Kagisaki K, Matsumoto K, Nakamura T, Matsuda H. In vivo gene transfection of hepatocyte growth factor attenuates ischemia-reperfusion injury in the heart: evidence of a role of HGF in endogenous myocardial protection. Circulation. 1997;96(suppl I):I-619. Abstract.
13. Belle EV, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, Isner JM. Potential angiogenetic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation. 1998;97:381-390.
14. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589-1596.
15. Katz SD, Biasucci L, Sabba C, Strom JA, Jondeau G, Galvao M, Solomon S, Nikolic SD, Forman R, LeJemtel TH. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol. 1992;19:918-925.
16. Nakamura M, Ishikawa M, Funakoshi T, Hashimoto K, Chiba M, Hiramori K. Attenuation endothelium-dependent peripheral vasodilation and clinical characteristics in patients with chronic heart failure. Am Heart J. 1994;128:1164-1169.
17. Mancini DM, Davis L, Wexler JP, Chadwick B, LeJemtel TH. Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term captopril therapy in heart failure. J Am Coll Cardiol. 1987;10:845-850.
18. Drexler H, Banhardt U, Meinertz T, Wollschlager H, Lehmann M, Just H. Contracting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure: a double-blind, placebo-controlled trial. Circulation. 1989;79:491-502.
19. Taniguchi T, Toi M, Tominaga T. Rapid induction of hepatocyte growth factor by heparin. Lancet. 1994;344:470.
20. Matsumoto K, Nakamura T. Heparin functions as a hepatotrophic factor by inducing production of hepatocyte growth factor. Biochem Biophys Res Commun. 1996;227:455-461.
21. Tsubouchi H, Niitani Y, Hiroko S, Nakayama H, Gohda E, Arakaki N, Sakiyama O, Takahashi K, Kimoto M, Kawakami S, Setoguchi M, Tachiyama T, Shin S, Arima T, Daikuhara Y. Levels of the human hepatocyte growth factor in serum of patients with various diseases determined by an enzyme-linked immunosorbent assay. Hepatology. 1991;13:1-5.
22. Sumida H, Yasue H, Yoshimura M, Okumura K, Ogawa H, Kugiyama K, Matsuyama K, Kikuta K, Morita E, Nakao K. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol. 1995;25:1105-1110.
23. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
24. Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, Daikoku S, Matsumoto T, Miyazaki S, Matsuoka H, Takishita S, Kangawa K, Matsuo H, Nonogi H. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J. 1998;135:21-28.
25. Schaper W, Kubin T. Is hepatocyte growth factor a protein with cardioprotective activity in the ischemic heart? Circulation. 1997;95:2471-2472.
26. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the rennin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981;63:645-651.
27. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparisons of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the studies of left ventricular dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
28. Topic N, Kramer B, Massie B. Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure. Am Heart J. 1982;104:1172-1179.
29. Kramer BL, Massie B, Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation. 1983;67:807-816.
30. Captopril Multicenter Research Group. A placebo controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 1983;2:755-763.
31. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
32. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptides as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet. 1993;341:1109-1113.
33. Mizuno Y, Yasue H, Oshima S, Yoshimura M, Ogawa H, Morita E, Saito T, Yamashita S, Noda K, Sumida H, Motoyama T, Soejima H, Nakao K. Effects of angiotensin-converting enzyme inhibitor on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction. J Cardiac Failure. 1997;3:287-293.
34. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-2069.
35. Tan L-B, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69:1185-1195.
36. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathway in normal and failing human hearts. Circ Res. 1990;66:883-890.